Document:

Exhibit 10.4

 

Elevation
Oncology, Inc. 

2021
Employee Stock Purchase Plan

 

1.            Purpose.
Elevation Oncology, Inc. adopted the Plan effective as of the Effective Date. The purpose of this Plan is to provide eligible
employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company, to enhance such
employees’ sense of participation in the affairs of the Company. Capitalized terms not defined elsewhere in the text are defined
in Section 28.

 

2.            Establishment
of Plan. The Company proposes to grant rights to purchase shares of Common Stock to eligible employees of the Company and
its Participating Corporations pursuant to this Plan. The Company intends this Plan to qualify as an “employee stock purchase plan”
under Section 423 of the Code (including any amendments to or replacements of such Section), and this Plan shall be so construed,
although the Company makes no undertaking or representation to maintain such qualification. Any term not expressly defined in this Plan
but defined for purposes of Section 423 of the Code shall have the same definition herein. In addition, with regard to offers of
options to purchase shares of Common Stock under the Plan to employees working for a Subsidiary or an Affiliate outside the United States,
this Plan authorizes the grant of options under a Non-Section 423 Component that is not intended to meet Section 423 requirements,
provided, to the extent necessary under Section 423 of the Code, the other terms and conditions of the Plan are met.

 

Subject to Section 14,
a total Two Hundred Twenty Eight Thousand Two Hundred Twenty Two (228,222) shares of Common Stock is reserved for issuance under this
Plan. In addition, on each January 1 for each of 2022 through 2031, the aggregate number of shares of Common Stock reserved for
issuance under the Plan shall be increased automatically by the number of shares equal to One percent (1%) of the total number of outstanding
shares of all classes of the Company’s common stock outstanding on the immediately preceding December 31st (rounded
down to the nearest whole share); provided, that the Board or the Committee may in its sole discretion reduce the amount of the
increase in any particular year. Subject to Section 14, no more than Four Million Five Hundred Sixty Four Thousand Four Hundred
Forty (4,564,440) shares of Common Stock may be issued over the term of this Plan. The number of shares initially reserved for issuance
under this Plan and the maximum number of shares that may be issued under this Plan shall be subject to adjustments effected in accordance
with Section 14. Any or all such shares may be granted under the Section 423 Component.

 

3.            ADMINISTRATION.
The Plan will be administered by the Committee. Subject to the provisions of this Plan and the limitations of Section 423 of
the Code or any successor provision in the Code, all questions of interpretation or application of this Plan shall be determined by the
Committee and its decisions shall be final and binding upon all eligible employees and Participants. The Committee will have full and
exclusive discretionary authority to construe, interpret and apply the terms of the Plan, to determine eligibility, to designate the
Participating Corporations, to determine whether Participating Corporations shall participate in the Section 423 Component or Non-Section 423
Component and to decide upon any and all claims filed under the Plan. Every finding, decision and determination made by the Committee
will, to the full extent permitted by law, be final and binding upon all parties. Notwithstanding any provision to the contrary in this
Plan, the Committee may adopt rules, sub-plans, and/or procedures relating to the operation and administration of the Plan designed to
comply with local laws, regulations or customs or to achieve tax, securities law or other objectives for eligible employees outside of
the United States. The Committee will have the authority to determine the Fair Market Value of the Common Stock (which determination
shall be final, binding and conclusive for all purposes) in accordance with Section 8 below and to interpret Section 8 of the
Plan in connection with circumstances that impact the Fair Market Value. Members of the Committee shall receive no compensation for their
services in connection with the administration of this Plan, other than standard fees as established from time to time by the Board for
services rendered by Board members serving on Board committees. All expenses incurred in connection with the administration of this Plan
shall be paid by the Company. For purposes of this Plan, the Committee may designate separate offerings under the Plan (the terms of
which need not be identical) in which eligible employees of one or more Participating Corporations will participate, and the provisions
of the Plan will separately apply to each such separate offering even if the dates of the applicable Offering Periods of each such offering
are identical. To the extent permitted by Section 423 of the Code, the terms of each separate offering under the Plan need not be
identical, provided that the rights and privileges established with respect to a particular offering are applied in an identical manner
to all employees of every Participating Corporation whose employees are granted options under that particular offering. The Committee
may establish rules to govern the terms of the Plan and the offering that will apply to Participants who transfer employment between
the Company and Participating Corporations or between Participating Corporations, in accordance with requirements under Section 423
of the Code to the extent applicable.

 

    1

     

    

 

4.            ELIGIBILITY.

 

(a)          Any
employee of the Company or the Participating Corporations is eligible to participate in an Offering Period under this Plan, except that
one or more of the following categories of employees may be excluded from coverage under the Plan if determined by the Committee (other
than where such exclusion is prohibited by applicable law):

 

(i)            employees
who do not meet eligibility requirements that the Committee may choose to impose (within the limits permitted by the Code);

 

(ii)           employees
who are not employed by the Company or a Participating Corporation prior to the beginning of such Offering Period or prior to such other
time period as specified by the Committee;

 

(iii)          employees
who are customarily employed for twenty (20) or less hours per week;

 

(iv)          employees
who are customarily employed for five (5) months or less in a calendar year;

 

(v)           (a) employees
who are “highly compensated employees” of the Company or any Participating Corporation (within the meaning of Section 414(q) of
the Code), or (b) any employees who are “highly compensated employees” with compensation above a specified level, who
is an officer and/or is subject to the disclosure requirements of Section 16(a) of the Exchange Act;

 

(vi)          employees
who are citizens or residents of a foreign jurisdiction (without regard to whether they are also a citizen of the United States or a
resident alien (within the meaning of Section 7701(b)(1)(A) of the Code)) if either (i) such employee’s participation
is prohibited under the laws of the jurisdiction governing such employee, or (ii) compliance with the laws of the foreign jurisdiction
would violate the requirements of Section 423 of the Code; and

 

(vii)         individuals
who provide services to the Company or any of its Participating Corporations who are reclassified as common law employees for any reason
except for federal income and employment tax purposes.

 

    2

     

    

 

The foregoing notwithstanding, an individual
shall not be eligible if his or her participation in the Plan is prohibited by the law of any country that has jurisdiction over him
or her, if complying with the laws of the applicable country would cause the Plan to violate Section 423 of the Code, or if he or
she is subject to a collective bargaining agreement that does not provide for participation in the Plan.

 

(b)            No
employee who, together with any other person whose stock would be attributed to such employee pursuant to Section 424(d) of
the Code, owns stock or holds options to purchase stock possessing five percent (5%) or more of the total combined voting power or value
of all classes of stock of the Company or its Parent or Subsidiary or who, as a result of being granted an option under this Plan with
respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total
combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary shall be granted an option to purchase
Common Stock under the Plan. Notwithstanding the foregoing, the rules of Section 424(d) of the Code shall apply in determining
share ownership and the extent to which shares held under outstanding equity awards are to be treated as owned by the employee.

 

5.            OFFERING
DATES.

 

(a)            Each
Offering Period of this Plan may be of up to twenty-seven (27) months duration and shall commence and end at the times designated by
the Committee. Each Offering Period shall consist of one or more Purchase Periods during which Contributions made by Participants are
accumulated under this Plan.

 

(b)            The
initial Offering Period shall commence on a date selected by the Committee. The initial Offering Period shall consist of one Purchase
Period (except as otherwise provided the Committee). Thereafter, a new Offering Period shall commence on such dates as are specified
by the Committee, with each such Offering Period also consisting of a single six (6)-month Purchase Period, except as otherwise provided
by an applicable sub-plan, or by the Committee. The Committee may at any time establish a different duration for an Offering Period or
Purchase Period to be effective after the next scheduled Purchase Date, up to a maximum duration of twenty-seven (27) months.

 

6.            PARTICIPATION
IN THIS PLAN.

 

(a)            Any
employee who is an eligible employee determined in accordance with Section 4 immediately prior to an Offering Periods will be eligible
to participate in this Plan, subject to the requirement of Section 6(b) hereof and the other terms and provisions of this Plan.

 

(b)            With
respect to any Offering Periods under this Plan, a Participant may elect to participate in this Plan by submitting an enrollment agreement,
or electronic representation thereof, to the Company and/or via the authorized third party administrator (the “Third Party
Administrator”) prior to the commencement of such Offering Period (or such earlier date as the Committee may determine)
to which such agreement relates, subject to the other terms and provisions of this Plan and in accordance with such rules as the
Committee may determine.

 

(c)            Once
an employee becomes a Participant in an Offering Period, then such Participant will automatically participate in each subsequent Offering
Period commencing immediately following the last day of the prior Offering Period at the same contribution level unless the Participant
withdraws or is deemed to withdraw from this Plan or terminates further participation in an Offering Period as set forth in Section 11
below, or otherwise notifies the Company of a change in the Participant’s contribution level by filing an additional subscription
agreement or electronic representation thereof with the Company and/or the Third Party Administrator, prior to the next Offering Period.
A Participant who is continuing participation pursuant to the preceding sentence is not required to file any additional enrollment agreement
in order to continue participation in this Plan; a Participant who is not continuing participation pursuant to the preceding sentence
is required to file an enrollment agreement prior to the commencement of the Offering Period (or such earlier date as the Committee may
determine) to which such agreement relates.

 

    3

     

    

 

7.            GRANT
OF OPTION ON ENROLLMENT. Becoming a Participant with respect to an Offering Period will constitute the grant (as of the Offering
Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of shares of Common Stock determined
by a fraction, the numerator of which is the amount accumulated in such Participant’s Contribution account during such Purchase
Period and the denominator of which is the lower of (i) eighty-five percent (85%) of the Fair Market Value of a share of Common
Stock on the Offering Date (but in no event less than the par value of a share of the Common Stock), or (ii) eighty-five percent
(85%) of the Fair Market Value of a share of the Common Stock on the Purchase Date (but in no event less than the par value of a share
of the Common Stock); and provided, further, that the number of shares of Common Stock subject to any option granted pursuant
to this Plan shall not exceed the lesser of (x) the maximum number of shares set by the Committee pursuant to Section 10(b) below
with respect to the applicable Purchase Date, or (y) the maximum number of shares which may be purchased pursuant to Section 10(a) below
with respect to the applicable Purchase Date.

 

8.            PURCHASE
PRICE. The Purchase Price per share at which a share of Common Stock will be sold in any Offering Period shall be eighty-five percent
(85%) of the lesser of:

 

(a)            The
Fair Market Value on the Offering Date; or

 

(b)            The
Fair Market Value on the Purchase Date.

 

9.            PAYMENT
OF PURCHASE PRICE; CONTRIBUTION CHANGES; SHARE ISSUANCES.

 

(a)            The
Purchase Price shall be accumulated by regular payroll deductions made during each Offering Period, unless the Committee determines that
contributions may be made in another form (including but not limited to with respect to categories of Participants outside the United
States that Contributions may be made in another form due to local legal requirements). The Contributions are made as a percentage of
the Participant’s Compensation in one percent (1%) increments not less than one percent (1%)] nor greater than fifteen percent
(15%) or such lower limit set by the Committee. “Compensation” shall mean base salary or regular hourly wages;
however, the Committee shall have discretion to adopt a definition of Compensation (or in foreign jurisdictions, equivalent cash compensation)
from time to time of all cash compensation reported on the employee's Form W-2 or corresponding local country tax return, including
without limitation base salary or regular hourly wages, bonuses, incentive compensation, commissions, overtime, shift premiums, pay during
leaves of absence, and draws against commissions (or in foreign jurisdictions, equivalent cash compensation). For purposes of determining
a Participant’s Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125
or 401(k) of the Code (or in foreign jurisdictions, equivalent deductions) shall be treated as if the Participant did not make such
election. Contributions shall commence on the first payday following the last Purchase Date and shall continue to the end of the Offering
Period unless sooner altered or terminated as provided in this Plan. Notwithstanding the foregoing, the terms of any sub-plan may permit
matching shares without the payment of any purchase price.

 

    4

     

    

 

(b)           A
Participant may decrease the rate of Contributions during an Offering Period by filing with the Company or a third party designated by
the Company a new authorization for Contributions, with the new rate to become effective no later than the second payroll period commencing
after the Company’s receipt of the authorization and continuing for the remainder of the Offering Period unless changed as described
below. A decrease in the rate of Contributions may be made once during any Offering Period, or more frequently under rules determined
by the Committee. A Participant may increase or decrease the rate of Contributions for any subsequent Offering Period by filing with
the Company or a third party designated by the Company a new authorization for Contributions prior to the beginning of such Offering
Period, or such other time period as specified by the Committee.

 

(c)           A
Participant may reduce his or her Contribution percentage to zero during an Offering Period by filing with the Company or a third party
designated by the Company a request for cessation of Contributions. Such reduction shall be effective beginning no later than the second
payroll period after the Company’s receipt of the request and no further Contributions will be made for the duration of the Offering
Period. Contributions credited to the Participant’s account prior to the effective date of the request shall be used to purchase
shares of Common Stock in accordance with Subsection (e) below. A reduction of the Contribution percentage to zero shall be treated
as such Participant’s withdrawal from such Offering Period and the Plan, effective as of the day after the next Purchase Date following
the filing date of such request with the Company.

 

(d)           All
Contributions made for a Participant are credited to his or her book account under this Plan and are deposited with the general funds
of the Company, except to the extent local legal restrictions outside the United States require segregation of such Contributions. No
interest accrues on the Contributions, except to the extent required due to local legal requirements. All Contributions received or held
by the Company may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions,
except to the extent necessary to comply with local legal requirements outside the United States.

 

(e)           On
each Purchase Date, so long as this Plan remains in effect and provided that the Participant has not submitted a signed and completed
withdrawal form before that date which notifies the Company and/or the Third Party Administrator that the Participant wishes to withdraw
from that Offering Period under this Plan and have all Contributions accumulated in the account maintained on behalf of the Participant
as of that date returned to the Participant, the Company shall apply the funds then in the Participant’s account to the purchase
of whole shares of Common Stock reserved under the option granted to such Participant with respect to the Offering Period to the extent
that such option is exercisable on the Purchase Date. The Purchase Price per share shall be as specified in Section 8 of this Plan.
Any fractional share, as calculated under this Subsection (e), shall be rounded down to the next lower whole share, unless the Committee
determines with respect to all Participants that any fractional share shall be credited as a fractional share. Any amount remaining in
a Participant’s account on a Purchase Date which is less than the amount necessary to purchase a full share of the Common Stock
shall be carried forward without interest (except to the extent necessary to comply with local legal requirements outside the United
States) into the next Purchase Period or Offering Period, as the case may be, unless otherwise required to be refunded or returned to
the Participant pursuant to this Section 9, Section 10(d), Section 11(b), Section 12, Section 13, Section 25,
or as otherwise provided by this Plan; however, the Committee may determine for future Offering Periods that such amounts shall be refunded
without interest. In the event that this Plan has been oversubscribed, all funds not used to purchase shares on the Purchase Date shall
be returned to the Participant, without interest (except to the extent required due to local legal requirements outside the United States).
No Common Stock shall be purchased on a Purchase Date on behalf of any employee whose participation in this Plan has terminated prior
to such Purchase Date, except to the extent required due to local legal requirements outside the United States.

 

    5

     

    

 

(f)           As
promptly as practicable after the Purchase Date, the Company shall issue shares for the Participant’s benefit representing the
shares purchased upon exercise of his or her option.

 

(g)           During
a Participant’s lifetime, his or her option to purchase shares hereunder is exercisable only by him or her. The Participant will
have no interest or voting right in shares covered by his or her option until such option has been exercised.

 

(h)           To
the extent required by applicable federal, state, local or foreign law, a Participant shall make arrangements satisfactory to the Company
and the Participating Corporation employing the Participant for the satisfaction of any withholding tax obligations that arise in connection
with the Plan. The Company or any Subsidiary or Affiliate, as applicable, may withhold, by any method permissible under the applicable
law, the amount necessary for the Company or Subsidiary or Affiliate, as applicable, to meet applicable withholding obligations, including
any withholding required to make available to the Company or Subsidiary or Affiliate, as applicable, any tax deductions or benefits attributable
to the sale or early disposition of shares of Common Stock by a Participant. The Company shall not be required to issue any shares of
Common Stock under the Plan until such obligations are satisfied.

 

10.          LIMITATIONS
ON SHARES TO BE PURCHASED.

 

(a)           Any
other provision of the Plan notwithstanding, no Participant shall purchase Common Stock with a Fair Market Value in excess of the following
limit:

 

(i)           In
the case of Common Stock purchased during an Offering Period that commenced in the current calendar year, the limit shall be equal to
(A) $25,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased in the current calendar
year (under this Plan and all other employee stock purchase plans of the Company or any Parent or Subsidiary).

 

(ii)          In
the case of Common Stock purchased during an Offering Period that commenced in the immediately preceding calendar year, the limit shall
be equal to (A) $50,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased (under
this Plan and all other employee stock purchase plans of the Company or any Parent or Subsidiary) in the current calendar year and in
the immediately preceding calendar year.

 

(iii)           In
the case of Common Stock purchased during an Offering Period that commenced two calendar years prior, the limit shall be equal to (A) $75,000
minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased (under this Plan and all other employee
stock purchase plans of the Company or any Parent or Subsidiary) in the current calendar year and in the two immediately preceding calendar
years.

 

For purposes of this Subsection (a), the
Fair Market Value of Common Stock shall be determined in each case as of the beginning of the Offering Period in which such Common Stock
is purchased. Employee stock purchase plans not described in Section 423 of the Code shall be disregarded. If a Participant is precluded
by this Subsection (a) from purchasing additional Common Stock under the Plan, then his or her Contributions shall automatically
be discontinued and shall automatically resume at the beginning of the earliest Purchase Period that will end in the next calendar year
(if he or she then is an eligible employee), provided that when the Company automatically resumes such Contributions, the Company must
apply the rate in effect immediately prior to such suspension.

 

(b)            In
no event shall a Participant be permitted to purchase more than 3,500 shares on any one Purchase Date or such lesser number as the Committee
shall determine. If a lower limit is set under this Subsection (b), then all Participants will be notified of such limit prior to
the commencement of the next Offering Period for which it is to be effective.

 

    6

     

    

 

(c)            If
the number of shares to be purchased on a Purchase Date by all Participants exceeds the number of shares then available for issuance
under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably
practicable and as the Committee shall determine to be equitable. In such event, the Company will give notice of such reduction of the
number of shares to be purchased under a Participant’s option to each Participant affected.

 

(d)            Any
Contributions accumulated in a Participant’s account which are not used to purchase stock due to the limitations in this Section 10,
and not covered by Section 9(e), shall be returned to the Participant as soon as administratively practicable after the end of the
applicable Purchase Period, without interest (except to the extent required due to local legal requirements outside the United States).

 

11.           WITHDRAWAL.

 

(a)            Each
Participant may withdraw from an Offering Period under this Plan pursuant to a method specified for such purpose by the Company. Such
withdrawal may be elected at any time prior to the end of an Offering Period, or such other time period as specified by the Committee.

 

(b)           Upon
withdrawal from this Plan, the accumulated Contributions shall be returned to the withdrawn Participant, without interest (except to
the extent required due to local legal requirements outside the United States), and his or her interest in this Plan shall terminate.
In the event a Participant voluntarily elects to withdraw from this Plan, he or she may not resume his or her participation in this Plan
during the same Offering Period, but he or she may participate in any Offering Period under this Plan which commences on a date subsequent
to such withdrawal by filing a new authorization for Contributions in the same manner as set forth in Section 6 above for initial
participation in this Plan.

 

(c)            To
the extent applicable, if the Fair Market Value on the first day of the current Offering Period in which a Participant is enrolled is
higher than the Fair Market Value on the last day of any applicable Purchase Period, (1) the Company will automatically withdraw
the Participant from the prior Offering Period and the Participant will be automatically enrolled in a new Offering Period, (2) the
old Offering Period is terminated, (3) the new Offering Period will be coterminous with the originally scheduled termination date
of the old Offering Period, unless otherwise determined by the Committee, and (4) any funds accumulated in a Participant’s
account prior to the first day of such new Offering Period will be applied to the purchase of shares on the Purchase Date preceding the
first day of such new Offering Period.

 

12.           TERMINATION
OF EMPLOYMENT. Termination of a Participant’s employment for any reason, including retirement, death, disability, or the failure
of a Participant to remain an eligible employee of the Company or of a Participating Corporation, immediately terminates his or her participation
in this Plan (except as required due to local legal requirements outside the United States). In such event, accumulated Contributions
credited to the Participant’s account will be returned to him or her or, in the case of his or her death, to his or her legal representative,
without interest (except to the extent required due to local legal requirements outside the United States). For purposes of this Section 12,
an employee will not be deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a Participating
Corporation in the case of sick leave, military leave, or any other leave of absence approved by the Company; provided that such
leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or
statute. The Company will have sole discretion to determine whether a Participant has terminated employment and the effective date on
which the Participant terminated employment, regardless of any notice period or garden leave required under local law.

 

    7

     

    

 

13.           RETURN
OF CONTRIBUTIONS. In the event a Participant’s interest in this Plan is terminated by withdrawal, termination of employment
or otherwise, or in the event this Plan is terminated by the Board, the Company shall deliver to the Participant all accumulated Contributions
credited to such Participant’s account. No interest shall accrue on the Contributions of a Participant in this Plan (except to
the extent required due to local legal requirements outside the United States).

 

14.            CAPITAL
CHANGES. If the number and class of outstanding shares is changed by a stock dividend, recapitalization, stock split, reverse stock
split, subdivision, combination, reclassification or similar change in the capital structure of the Company, without consideration, then
the Committee shall adjust the number and class of Common Stock that may be delivered under the Plan, the Purchase Price per share and
the number of shares of Common Stock covered by each option under the Plan which has not yet been exercised, and the numerical limits
of Sections 2 and 10 shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company
and in compliance with the applicable securities laws; provided that fractions of a share will not be issued.

 

15.            NONASSIGNABILITY.
Neither Contributions credited to a Participant’s account nor any rights with regard to the exercise of an option or to receive
shares under this Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent
and distribution or as provided in Section 22 below) by the Participant. Any such attempt at assignment, transfer, pledge or other
disposition shall be void and without effect.

 

16.            USE
OF PARTICIPANT FUNDS AND REPORTS. The Company may use all Contributions received or held by it under the Plan for any corporate purpose,
and the Company will not be required to segregate Participant Contributions (except to the extent required due to local legal requirements
outside the United States). Until shares are issued, Participants will only have the rights of an unsecured creditor unless otherwise
required under local law. Each Participant shall receive, or have access to, promptly after the end of each Purchase Period a report
of his or her account setting forth the total Contributions accumulated, the number of shares purchased, the per share price thereof
and the remaining cash balance, if any, carried forward to the next Purchase Period or Offering Period, as the case may be.

 

17.            NOTICE
OF DISPOSITION. Each U.S. taxpayer Participant shall notify the Company in writing if the Participant disposes of any of the shares
purchased in any Offering Period pursuant to this Plan if such disposition occurs within two (2) years from the Offering Date or
within one (1) year from the Purchase Date on which such shares were purchased (the “Notice Period”).
The Company may, at any time during the Notice Period, place a legend or legends on any certificate representing shares acquired pursuant
to this Plan requesting the Company’s transfer agent to notify the Company of any transfer of the shares. The obligation of the
Participant to provide such notice shall continue notwithstanding the placement of any such legend on the certificates.

 

18.            NO
RIGHTS TO CONTINUED EMPLOYMENT. Neither this Plan nor the grant of any option hereunder shall confer any right on any employee to
remain in the employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation
to terminate such employee’s employment.

 

19.            EQUAL
RIGHTS AND PRIVILEGES. All eligible employees granted an option under this Plan that is intended to meet Code Section 423 requirements
shall have equal rights and privileges with respect to this Plan or within any separate offering under the Plan so that this Plan qualifies
as an “employee stock purchase plan” within the meaning of Section 423 or any successor provision of the Code and the
related regulations. Any provision of this Plan which is inconsistent with Section 423 or any successor provision of the Code, without
further act or amendment by the Company, the Committee or the Board, shall be reformed to comply with the requirements of Section 423.
This Section 19 shall take precedence over all other provisions in this Plan.

 

    8

     

    

 

20.          NOTICES.
All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have
been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the
receipt thereof.

 

21.          TERM;
STOCKHOLDER APPROVAL. This Plan will become effective on the Effective Date. This Plan shall be approved by the stockholders of the
Company, in any manner permitted by applicable corporate law, within twelve (12) months before or after the date this Plan is adopted
by the Board. No purchase of shares that are subject to such stockholder approval before becoming available under this Plan shall occur
prior to stockholder approval of such shares and the Board or Committee may delay any Purchase Date and postpone the commencement of
any Offering Period subsequent to such Purchase Date as deemed necessary or desirable to obtain such approval (provided that if a Purchase
Date would occur more than six (6) months after commencement of the Offering Period to which it relates, then such Purchase Date
shall not occur and instead such Offering Period shall terminate without the purchase of such shares and Participants in such Offering
Period shall be refunded their Contributions without interest). This Plan shall continue until the earlier to occur of (a) termination
of this Plan by the Board (which termination may be effected by the Board at any time pursuant to Section 25 below), (b) issuance
of all of the shares of Common Stock reserved for issuance under this Plan, or (c) the tenth anniversary of the Effective Date.

 

22.          DESIGNATION
OF BENEFICIARY.

 

(a)            If
authorized by the Committee, a Participant may file a written or electronic designation of a beneficiary who is to receive any shares
and cash, if any, from the Participant’s account under this Plan in the event of such Participant’s death subsequent to the
end of a Purchase Period but prior to delivery to him of such shares and cash. In addition, if authorized by the Committee, a Participant
may file a written or electronicf designation of a beneficiary who is to receive any cash from the Participant’s account under
this Plan in the event of such Participant’s death prior to a Purchase Date. Such form shall be valid only if it was filed with
the Company and/or the Third Party Administrator at the prescribed location before the Participant’s death.

 

(b)            If
authorized by the Company, such designation of beneficiary may be changed by the Participant at any time by written notice filed with
the Company at the prescribed location before the Participant’s death. In the event of the death of a Participant and in the absence
of a beneficiary validly designated under this Plan who is living at the time of such Participant’s death, the Company shall deliver
such cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed
(to the knowledge of the Company) the Company, in its discretion, may deliver such shares or cash to the legal heirs of the Participant.

 

23.          CONDITIONS
UPON ISSUANCE OF SHARES; LIMITATION ON SALE OF SHARES. Shares shall not be issued with respect to an option unless the exercise of
such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic
or foreign, including, without limitation, the U.S. Securities Act of 1933, as amended, the Exchange Act, the rules and regulations
promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which the shares may then be listed,
exchange control restrictions and/or securities law restrictions outside the United States, and shall be further subject to the approval
of counsel for the Company with respect to such compliance. Shares may be held in trust or subject to further restrictions as permitted
by any subplan.

 

    9

     

    

 

24.          APPLICABLE
LAW. The Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the State of Delaware.

 

25.          AMENDMENT
OR TERMINATION. The Committee, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time
and for any reason. Unless otherwise required by applicable law, if the Plan is terminated, the Committee, in its discretion, may elect
to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the
next Purchase Date (which may be sooner than originally scheduled, if determined by the Committee in its discretion), or may elect to
permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section 14). If an Offering
Period is terminated prior to its previously-scheduled expiration, all amounts then credited to Participants’ accounts for such
Offering Period, which have not been used to purchase shares of Common Stock, shall be returned to those Participants (without interest
thereon, except as otherwise required under local laws) as soon as administratively practicable. Further, the Committee will be entitled
to change the Purchase Periods and Offering Periods, limit the frequency and/or number of changes in the amount contributed during an
Offering Period, establish the exchange ratio applicable to amounts contributed in a currency other than U.S. dollars, permit payroll
withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the administration of the
Plan, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward
the purchase of Common Stock for each Participant properly correspond with amounts contributed from the Participant’s base salary
and other eligible compensation, and establish such other limitations or procedures as the Committee determines in its sole discretion
advisable which are consistent with the Plan. Such actions will not require stockholder approval or the consent of any Participants.
However, no amendment shall be made without approval of the stockholders of the Company (obtained in accordance with Section 21
above) within twelve (12) months of the adoption of such amendment (or earlier if required by Section 21) if such amendment would:
(a) increase the number of shares that may be issued under this Plan; or (b) change the designation of the employees (or class
of employees) eligible for participation in this Plan. In addition, in the event the Board or Committee determines that the ongoing operation
of the Plan may result in unfavorable financial accounting consequences, the Board or Committee may, in its discretion and, to the extent
necessary or desirable, modify, amend or terminate the Plan to reduce or eliminate such accounting consequences including, but not limited
to: (i) amending the definition of compensation, including with respect to an Offering Period underway at the time; (ii) altering
the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price; (iii) shortening
any Offering Period by setting a Purchase Date, including an Offering Period underway at the time of the Committee’s action; (iv) reducing
the maximum percentage of Compensation a participant may elect to set aside as Contributions; and (v) reducing the maximum number
of shares a Participant may purchase during any Offering Period. Such modifications or amendments will not require approval of the stockholders
of the Company or the consent of any Participants.

 

26.           CORPORATE
TRANSACTIONS. In the event of a Corporate Transaction, the Offering Period for each outstanding right to purchase Common Stock will
be shortened by setting a new Purchase Date and will end on the new Purchase Date. The new Purchase Date shall occur on or prior to the
consummation of the Corporate Transaction, as determined by the Board or Committee, and the Plan shall terminate on the consummation
of the Corporate Transaction.

 

    10

     

    

 

27.          CODE
SECTION 409A; TAX QUALIFICATION.

 

(a)            Options
granted under the Plan generally are exempt from the application of Section 409A of the Code. However, options granted to U.S. taxpayers
which are not intended to meet the Code Section 423 requirements are intended to be exempt from the application of Section 409A
of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent.
Subject to Subsection (b), options granted to U.S. taxpayers outside of the Code Section 423 requirements shall be subject to such
terms and conditions that will permit such options to satisfy the requirements of the short-term deferral exception available under Section 409A
of the Code, including the requirement that the shares of Common Stock subject to an option be delivered within the short-term deferral
period. Subject to Subsection (b), in the case of a Participant who would otherwise be subject to Section 409A of the Code, to the
extent the Committee determines that an option or the exercise, payment, settlement or deferral thereof is subject to Section 409A
of the Code, the option shall be granted, exercised, paid, settled or deferred in a manner that will comply with Section 409A of
the Code, including Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations
or other guidance that may be issued after the Effective Date. Notwithstanding the foregoing, the Company shall have no liability to
a Participant or any other party if the option that is intended to be exempt from or compliant with Section 409A of the Code is
not so exempt or compliant or for any action taken by the Committee with respect thereto.

 

(b)            Although
the Company may endeavor to (i) qualify an option for favorable tax treatment under the laws of the United States or jurisdictions
outside of the United States or (ii) avoid adverse tax treatment (e.g., under Section 409A of the Code), the Company
makes no representation to that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax treatment,
notwithstanding anything to the contrary in this Plan, including Subsection (a). The Company shall be unconstrained in its corporate
activities without regard to the potential negative tax impact on Participants under the Plan.

 

28.          DEFINITIONS.

 

(a)            “Affiliate”
means any entity, other than a Subsidiary or Parent, (i) that, directly or indirectly, is controlled by, controls or is under common
control with, the Company and (ii)  in which the Company has a significant equity interest, in either case as determined by the
Committee, whether now or hereafter existing.

 

(b)            “Board”
shall mean the Board of Directors of the Company.

 

(c)            “Code”
shall mean the U.S. Internal Revenue Code of 1986, as amended.

 

(d)            “Committee”
shall mean the Compensation Committee of the Board that consists exclusively of one or more members of the Board appointed by the Board.

 

(e)            “Common
Stock” shall mean the common stock of the Company.

 

(f)            “Company”
shall mean Elevation Oncology, Inc.

 

(g)            “Contributions”
means payroll deductions taken from a Participant's Compensation and used to purchase shares of Common Stock under the Plan and, to the
extent payroll deductions are not permitted by applicable laws (as determined by the Committee in its sole discretion) contributions
by other means, provided, however, that allowing such other contributions does not jeopardize the qualification of the Plan as an “employee
stock purchase plan” under Section 423 of the Plan.

 

    11

     

    

 

(h)            “Corporate
Transaction” means the occurrence of any of the following events: (i) any “person” (as such term is used
in Sections 13(d) and 14(d) of the Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3
of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total
voting power represented by the Company’s then outstanding voting securities; or (ii) the consummation of the sale or disposition
by the Company of all or substantially all of the Company’s assets; or (iii) the consummation of a merger or consolidation
of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities
of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities
of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

 

(i)            “Effective
Date” shall mean the date on which the Registration Statement covering the initial public offering of the shares of Common
Stock is declared effective by the U.S. Securities and Exchange Commission.

 

(j)            “Exchange
Act” means the U.S. Securities Exchange Act of 1934, as amended.

 

(k)            “Fair
Market Value” shall mean, as of any date, the value of a share of Common Stock determined as follows:

 

(1)           if
such Common Stock is then quoted on the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (collectively,
the “Nasdaq Market”), its closing price on the Nasdaq Market on the date of determination, or if there are
no sales for such date, then the last preceding business day on which there were sales, as reported in The Wall Street Journal
or such other source as the Board or the Committee deems reliable;

 

(2)           if
such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of determination
on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in The Wall Street
Journal or such other source as the Board or the Committee deems reliable;

 

(3)           if
such Common Stock is publicly traded but is neither quoted on the Nasdaq Market nor listed or admitted to trading on a national securities
exchange, the average of the closing bid and asked prices on the date of determination as reported in The Wall Street Journal or
such other source as the Board or the Committee deems reliable;

 

(4)           if
none of the foregoing is applicable, by the Board or the Committee in good faith.

 

(l)           “Non-Section 423
Component” means the part of the Plan which is not intended to meet the requirements set forth in Section 423 of the
Code.

 

(m)          “Notice
Period” shall mean within two (2) years from the Offering Date or within one (1) year from the Purchase Date
on which such shares were purchased.

 

(n)           “Offering
Date” shall mean the first business day of each Offering Period.

 

    12

     

    

 

(o)           “Offering
Period” shall mean a period with respect to which the right to purchase Common Stock may be granted under the Plan, as
determined by the Committee pursuant to Section 5(a).

 

(p)           “Parent”
shall have the same meaning as “parent corporation” in Sections 424(e) and 424(f) of the Code.

 

(q)           “Participant”
shall mean an eligible employee who meets the eligibility requirements set forth in Section 4 and who elects to participate in this
Plan pursuant to Section 6(b).

 

(r)            “Participating
Corporation” shall mean any Parent, Subsidiary or Affiliate that the Committee designates from time to time as eligible
to participate in this Plan. For purposes of the Section 423 Component, only the Parent and Subsidiaries may be Participating Corporations,
provided, however, that at any given time a Parent or Subsidiary that is a Participating Corporation under the Section 423 Component
shall not be a Participating Corporation under the Non-Section 423 Component. The Committee may provide that any Participating Corporation
shall only be eligible to participate in the Non-Section 423 Component.

 

(s)           “Plan”
shall mean this Elevation Oncology, Inc. 2021 Employee Stock Purchase Plan, as may be amended from time to time.

 

(t)            “Purchase
Date” shall mean the last business day of each Purchase Period.

 

(u)           “Purchase
Period” shall mean a period during which Contributions may be made toward the purchase of Common Stock under the Plan,
as determined by the Committee pursuant to Section 5(b).

 

(v)           “Purchase
Price” shall mean the price at which Participants may purchase shares of Common Stock under the Plan, as determined pursuant
to Section 8.

 

(w)           “Section 423
Component” means the part of the Plan, which excludes the Non-Section 423 Component, pursuant to which options to
purchase shares of Common Stock under the Plan that satisfy the requirements for “employee stock purchase plans” set forth
in Section 423 of the Code may be granted to eligible employees.

 

(x)            “Subsidiary”
shall have the same meaning as “subsidiary corporation” in Sections 424(e) and 424(f) of the Code.

 

    13Exhibit 10.9

 

July 12, 2019

 

Shawn M. Leland, PharmD, RPh

[*****]

[*****]

 

Re: Executive Employment Agreement

 

Dear Shawn:

 

On behalf of 14ner Oncology, Inc.
(the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”)
is to set forth the terms of your employment with the Company, should you accept our offer.

 

1.            You
will be employed to serve as the Company’s Chief Business Officer, effective as of July 12, 2019 (the “Effective Date”).
You will be a full-time employee of the Company, and you will report to the Chief Executive Officer (the “CEO”) and have such
duties and responsibilities as are customary for such positions. You agree to devote your full business time, best efforts, skill, knowledge,
attention and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities
as an employee of the Company. Upon your commencement of employment with the Company, and so long as you are employed by the Company as
its Chief Business Officer or other C-level position, you shall serve as a member of the Company’s Board of Directors (the “Board”),
with no additional remuneration payable for such service. Upon your separation from employment with the Company or your otherwise no longer
serving as the Company’s Chief Business Officer or other C-level position, you shall, at the Board’s request, resign from
the Board. You agree to abide by the rules, regulations, personnel practices and policies of the Company and any changes therein that
may be adopted from time to time by the Company. Initially, you will work on a remote basis. Should the Company establish a principal
place of business operations, you will be expected to spend a meaningful amount of time at such location on terms and conditions as may
be agreed between you and the Company.

 

2.            Your
base salary will be at the rate of $26,250 per monthly (equivalent to an annualized base salary of $315,000), subject to tax and other
withholdings as required by law, and will be paid on the regularly scheduled payroll dates of the Company. The Board may elect to increase
your base salary periodically based on your performance and/or industry standards for similarly situated executives.

 

3.            Following
the end of each fiscal year and subject to the approval of the Company’s Board (or a committee thereof), you will be eligible for
a retention and performance bonus, targeted at 40% ($94,500, a 75% prorated portion of $126,000 for 2019) of your annualized base salary
as determined by the Board (or a committee thereof) in good faith based on your individual performance and the Company’s performance
during the applicable fiscal year, including, without limitation, based on the completion of or progress towards the deliverables listed
in Attachment A as it relates to 2019. If a bonus is awarded, unless otherwise specifically provided by the Board or committee administering
such plan, it shall be paid on or before January 31st of the year following the year in which such bonus was earned. You must be
an active employee of the Company on the date any bonus is distributed in order to be eligible for and to earn a bonus award, as it also
serves as an incentive to remain employed by the Company. The Board may elect to increase your retention and performance bonus target
based on your performance and/or industry standards for similarly situated executives.

 

    1

     

    

 

4.            You
may participate in any and all benefit programs that the Company establishes and makes available to its employees from time to time, provided
you are eligible under (and subject to all provisions of) the plan documents governing those programs. The benefit programs made available
by the Company, and the rules, terms and conditions for participation in such benefit programs, may be changed by the Company at any time
without advance notice (other than as required by such programs or under law). Until and unless the Company adopts a group health plan
that applies to all Company employees, the Company will bear the cost of health insurance for you [and your immediate family which may
be effected by reimbursing COBRA premiums for continuation coverage with your former employer], provided, however, that such amount shall
be subject to applicable taxes and withholdings. You will also be entitled to indemnification by the Company with respect to your service
as an officer and director of the Company pursuant to an Indemnification Agreement substantially similar to the NVCA form agreement.

 

5.            You
are eligible for six (6) weeks of vacation per calendar year to be taken at such times as will not materially interfere with the
performance of your duties. The number of vacation days for which you are eligible shall accrue at the rate of 1.66 days per month that
you are employed during such calendar year. Up to three (7) vacation days earned in one calendar year may be carried forward and
used in the subsequent calendar year.

 

6.            Subject
to the approval of the Board, within sixty days of the Effective Date, the Company will grant to you a stock option (the “Initial
Option Grant”) under the Company’s 2019 Stock Incentive Plan (the “Stock Plan”) to purchase an aggregate number
of shares of common stock of the Company as shall equal 3% of the fully diluted shares of the Company’s common stock (assuming that
all commitments to invest in the Company’s Series A preferred financing are met, and giving effect to the conversion to common
stock of all outstanding shares of preferred stock and to the shares available for issuance or outstanding under the Company’s Stock
Plan) (the “Fully Diluted Shares”), at an exercise price equal to the fair market value of the common stock on the date of
grant, as determined by the Board. The Initial Option Grant will be evidenced in writing by, and subject to the terms of the Stock Plan
and a stock option agreement provided by the Company, which agreement will specify that (a) the options subject to the Initial Option
Grant will vest, subject to your continued service, (x) as to 25% of the underlying shares on July 1, 2020, and (y) as
to the balance in equal 1/36th monthly installments thereafter until the fourth anniversary of July 1, 2019; and (b) the options
subject to the Initial Option Grant shall vest, subject to your continued service, as to 100% of the underlying shares if, within 12 months
following a Change of Control, (i) your employment with the Company or its acquirer or successor is terminated without Cause (as
defined below), or (ii) you resign from employment with the Company or its acquirer or successor with Good Reason (as defined below).

 

    2

     

    

 

7.            In
addition, until such time as the Company has raised an aggregate of $75,000,000 in preferred equity financing (the “Trigger Date”),
subject to the approval of the Board and your continued employment with the Company, you will be granted one or more additional stock
options (the “Additional Options”) under the Stock Plan to purchase an aggregate number of shares of common stock of the Company
as shall equal, when added to the Initial Option Grant, 3% of the fully diluted shares of the Company’s common stock (giving effect
to the conversion to common stock of outstanding shares of preferred stock sold for the aggregate amount of $75,000,000, and to the shares
available for issuance or outstanding under the Stock Plan, but not to any shares of preferred stock for consideration in excess of $75,000,000),
at an exercise price equal to the fair market value of the common stock on the date of grant, as determined by the Board. For clarity,
it is the intent of this clause that between the Initial Option Grant and the Additional Options, you will hold options to purchase stock
equal to a total of 3% of the Company’s capital stock outstanding on a fully-diluted basis until such time as the closing of the
issuance of shares of preferred stock of the Company in the aggregate amount of $75,000,000. The Additional Options will be evidenced
in writing by, and subject to the terms of the Stock Plan and stock option agreements provided by the Company, which agreements will specify
that (a) the Additional Options will vest, subject to your continued service, (x) as to 25% of the underlying shares on the
one-year anniversary of the equity financing giving rise to such Additional Options, and (y) as to the balance in equal 1/36th monthly
installments thereafter until the fourth anniversary of the equity financing giving rise to such Additional Options; and (b) the
Additional Options shall have the same acceleration provisions as the Initial Option Grant. Furthermore, the Board may elect to grant
you additional stock options based on your performance, a material increase in the number of Fully Diluted Shares and/or industry standards
for similarly situated executives.

 

8.            As
a material inducement to investors in the Company, you and the Company will enter into the Stock Restriction Agreement attached hereto
as Attachment B, which will provide the Company with a right of repurchase as to the 2,083,333 shares of Common Stock of the Company
you currently own (the “Founder Shares”). The Company’s right of repurchase shall lapse as to 1/48 of the Founder Shares
monthly over four years from July 1, 2019; provided, however, that such right of repurchase shall lapse as to 100% of the Founder
Shares immediately (a) prior to the effective date of a Change of Control (as defined below), (b) upon the Company’s termination
of your employment without Cause (as defined below), and (c) upon your resignation for Good Reason (as defined below).

 

9.            Without
otherwise limiting the “at-will” nature of your employment, if your employment is terminated by the Company without Cause
or by you for Good Reason (each as defined below), and provided you execute and allow to become effective (within 60 days following the
termination or such shorter period (of not less than twenty-one (21) days) as may be directed by the Company) a severance and release
of claims agreement in a form prescribed by the Company (which will include, at a minimum, a release of all releasable claims and post-employment
confidentiality, non-disparagement, non-competition, non-solicitation and cooperation obligations) (the “Release Agreement”),
the Company will pay you as severance pay an aggregate amount equivalent to six (6) months of your then current base salary, less
all applicable taxes and withholdings, which severance pay will be paid ratably in accordance with the Company’s regular payroll
practices beginning in the Company’s first regular payroll cycle after the Release Agreement becomes effective; provided, however,
that if the 60th day referenced above occurs in the calendar year following the date of your termination, then the severance pay shall
begin no earlier than January 1 of such subsequent calendar year. During the six (6) month severance period, the Company will
bear the cost of health insurance for you and your immediate family on substantially the terms applicable prior to the termination of
your employment.

 

    3

     

    

 

10.          For
purposes of this Agreement:

 

“Cause”
means any of: (a) your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude
or any felony; or (b) a good faith finding by the Board in its sole discretion that you have (i) engaged in dishonesty, willful
misconduct or gross negligence that has a material adverse effect on the Company, (ii) committed an act that materially injures the
reputation, business or business relationships of the Company, (iii) materially breached the terms of any invention and non-disclosure
agreement or non-competition and non-solicitation agreement with the Company which breach is not cured within ten days written notice
thereof; or (iv) failed or refused to comply in any material respect with the Company’s material policies or procedures and
in a manner that materially injures or would reasonably be expected to materially injure the reputation, business or business relationships
of the Company, provided that in the case of (iv) that you were given written notice of such violation or failure by the Board and
a period of 30 days to cure (provided that the Board determines that such violation or failure is curable).

 

“Change of
Control” shall mean, regardless of form thereof, consummation of (a) the sale of all or substantially all of the assets of
the Company on a consolidated basis to an unrelated person or entity, (b) a merger, reorganization or consolidation in which the
outstanding shares of capital stock of the Company are converted into or exchanged for securities of the successor entity and the holders
of the Company’s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting
power of the successor entity immediately upon completion of such transaction, (c) the sale of all or a majority of the outstanding
capital stock of the Company to an unrelated person or entity or (d) any other transaction in which the owners of the Company’s
outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the successor
entity immediately upon completion of the transaction; provided, however, that “Change of Control” shall not include any financing
transaction of the Company (whether public or private) that would otherwise be and/or trigger a “Change of Control” under
(c) and/or (d) above.

 

“Good Reason”
shall mean (i) any action by the Company which results in a material diminution in such position, authority, duties or responsibilities,
(ii) a material reduction in the aggregate of your base compensation and benefits, other than a reduction in monthly base salary
of no more than twenty percent (20%) as a result of across-the- board reductions or terminations affecting employees of the Company generally,
or (iii) the Company’s material breach of Paragraph 3 of this Agreement; provided, however, that the conditions described immediately
above in clauses (i) through (iii) shall not give rise to a termination for Good Reason, unless you have notified the Company
in writing within thirty (30) days of the first occurrence of the facts and circumstances claimed to provide a basis for the termination
for Good Reason, the Company has failed to correct the condition within thirty (30) days after the Company’s receipt of such written
notice, and you actually terminate employment with the Company within sixty (60) days of the first occurrence of the condition.

 

    4

     

    

 

11.          You
will be required to execute a Proprietary Information, Inventions, Non- Competition and Non-Solicitation Agreement in the form attached
as Attachment C (“Proprietary Information Agreement”) as a condition of employment.

 

12.          You
represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing (or that purports to
prevent) you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent
with the terms of this letter.

 

13.          You
agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States,
as required by the Immigration Reform and Control Act of 1986. You acknowledge and agree that your employment is subject to and conditioned
upon your eligibility to work in the United States.

 

14.          This
letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter
the Company’s policy of employment at will, under which both you and the Company remain free to terminate the employment relationship,
with or without cause, at any time, with or without notice. Although your job duties, title, compensation and benefits, as well as the
Company's personnel policies and procedures, may change from time to time, the "at-will" nature of your employment may only
be changed by a written agreement signed by you and the Board of Directors, which expressly states the intention to modify the at-will
nature of your employment. Similarly, nothing in this letter other than Paragraph 9 shall be construed as an agreement, either express
or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.

 

15.          The
Company’s offer of at-will employment is contingent upon your authorization and successful completion of background and reference
checks. You will be required to execute authorizations for the Company to obtain consumer reports and/or investigative consumer reports
and use them in conducting background checks as a condition to your employment. The Company may obtain background reports both pre-employment
and from time to time during your employment with the Company, as necessary.

 

16.          The
Company's premises, including all workspaces, furniture, documents, and other tangible materials, and all information technology resources
of the Company (including computers, data and other electronic files, and all internet and email, whether on Company premises or remote)
are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with regard
to any Company premises, materials, resources, or information.

 

17.          This
offer letter is your formal offer of employment and supersedes any and all prior or contemporaneous agreements, discussions and understandings,
whether written or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes
under this letter will be governed by the laws of the State of Delaware.

 

* * *

 

    5

     

    

 

If you agree with the provisions
of this letter, please sign the enclosed duplicate of this letter in the space provided below and return it to me, by July 12, 2019.
If you do not accept this offer by this date, this offer will be revoked.

 

	 	Very Truly Yours,

 

	 	By:	 /s/ Steve Elms

	 	Name: Steve Elms
	 	Title: CEO

 

The foregoing correctly sets forth the terms of
my employment by 14ner Oncology, Inc. I am not relying on any representations pertaining to my employment other than those set forth
above. I have read, understand, and agree to all of the above and hereby accept the Company’s offer of employment on the above terms
and conditions. I understand that my employment with the Company is considered “at will” meaning that either the Company or
I may terminate this employment relationship at any time for any reason without cause or notice. I further understand and agree that my
employment is contingent upon my execution of the Proprietary Information Agreement.

 

	/s/ Shawn Leland	 	Date:	                     7/12/2019
	Name: Shawn M. Leland, PharmD, RPh	 	 	 

 

    6

     

    

 

Attachment A

 

Bonus Criteria for 2019

 

Completion of the Milestone Closing pursuant to
the Company’s Series A Preferred Stock Purchase Agreement

 

    1

     

    

 

Attachment B

 

Stock Restriction Agreement

 

    1

     

    

 

Attachment C

 

Proprietary Information Agreement

 

    1

     

    

 

Shawn Leland

 

PROPRIETARY
INFORMATION, INVENTIONS,

NON-COMPETITION AND NON-SOLICITATION AGREEMENT

 

This Proprietary Information, Inventions,
Non-Competition and Non-Solicitation Agreement (“Agreement”) is made in consideration for my employment by 14ner Oncology, Inc.,
a Delaware corporation (the “Company”), and compensation now and hereafter paid to me. I understand and agree as follows:

 

1.             NONDISCLOSURE
AND USE. All Proprietary Information (as defined below) is and shall remain the sole and exclusive property of the Company. At all
times during my employment and afterwards I will not disclose or use any Proprietary Information, except as required in connection with
my work for the Company. I will take reasonable precautions to safeguard the Proprietary Information. I understand that I am also prohibited
from accessing the Company’s computer systems and databases for any unauthorized, improper or competitive purpose, both while employed
and thereafter. The term “Proprietary Information” means any information that relates to the Company’s actual
or anticipated business or research and development, technical data, trade secrets or know-how, including, but not limited to, research,
product plans or other information regarding the Company’s products or services and markets therefor, customer lists and customers,
software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information,
marketing, finance, other business information or other non-public information that a competitor of the Company could use to the competitive
disadvantage of the Company. I further understand that Proprietary Information (i) includes the foregoing information even if disclosed
to me in connection with the contemplation of my becoming an employee of the Company, i.e., prior to the effective date, (ii) does
not include any of the foregoing items that is or becomes publicly known through no wrongful act or omission of mine or of others who
were under confidentiality obligations as to the item or items involved. I further understand that, in accordance with the Defend Trade
Secrets Act of 2016, I will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure
of a Company trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly,
or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or is made in a complaint or other
document that is filed under seal in a lawsuit or other proceeding. I further understand that if I file a lawsuit for retaliation for
reporting a suspected violation of law, I may disclose the Company’s trade secrets to my attorney and use the trade secret
information in the court proceeding if any document containing the trade secret is filed under seal and I do not disclose the trade secret,
except pursuant to court order.

 

I will not disclose or use any information received
by the Company from third parties, except as required in connection with my work for the Company. I will not improperly use or disclose
any confidential information or trade secrets of any third party or former employer to whom I have an obligation of confidentiality. My
performance of all the terms of this Agreement and as an employee of the Company does not breach any agreement by which I am legally bound,
and I agree not to become a party to any such agreement.

 

    1

     

    

 

2.             ASSIGNMENT
OF INVENTIONS. I agree to assign and hereby assign to the Company upon creation all my right,
title and interest in and to any and all inventions, trade secrets, confidential and proprietary information, and work-product I conceive,
create or develop, whether or not eligible for or covered by patent, copyright or trade secret protection (collectively, “Inventions”)
and whether or not such Inventions constitute works for hire or would otherwise belong to the Company by operation of law, which (i) are
related to the Company’s actual or demonstrably anticipated business or research and development or (ii) were developed during
Company time or using Company resources, that become known to, or are made, conceived, reduced to practice or learned by me, either alone
or jointly with others, during the period of my employment with the Company (“Company Inventions”). All original works
of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by copyright
are “works made for hire” pursuant to United States Copyright Act (17 U.S.C. §101). I further waive any moral rights,
if any, I may have in any copyrightable subject matter of any Company Inventions. I will keep an adequate and current record of all
Proprietary Information and Company Inventions, which records shall be the property of the Company.

 

I will not incorporate any non-assignable inventions
(defined below) or Prior Inventions (defined below) into any work I perform for the Company without the Company’s prior written
consent, and, if I do, the Company is hereby granted a nonexclusive, royalty-free, irrevocable, perpetual, fully-paid, worldwide license
(with rights to sublicense) in and to all present and future rights in the same. I will promptly disclose to the Company all inventions
I develop by myself or jointly with others which I believe are “non-assignable inventions” under applicable law. For clarity,
work or inventions I made prior to the commencement of my employment with the Company which are owned in whole or in part by me are described
on the signature page hereto; or, if left blank, I affirm there are no such “Prior Inventions.”

 

During my employment and thereafter, I will
assist the Company in every proper way to obtain and enforce its intellectual property rights, it being understood that the Company shall
compensate me at a reasonable rate after my termination for the time actually spent by me and for any reasonable expenses actually incurred
by me at the Company’s request. If the Company is unable for any reason to secure my signature in connection with obtaining or enforcing
the Company’s intellectual property rights, then I hereby irrevocably appoint the Company and its duly authorized officers and agents
as my agent and attorney in fact, to act on my behalf and to execute and file any required documents and to do all other lawfully permitted
acts in furtherance thereof as if done by me.

 

3.             NO
CONFLICTS OR SOLICITATION. Due to the nature of my position with the Company, I will have
access to and learn the Company’s Proprietary Information which is commercially valuable and of great importance to the Company.
To protect the Company’s Proprietary Information, during my employment, I will not engage in any other employment or other
activity that is related to the business in which the Company is now involved or becomes involved or has plans to become involved, nor
will I engage in any other activities that conflict with my obligations to the Company.

 

In addition, during my employment and for a period
of one year following the termination of my employment with the Company for any reason, I will not, either directly or indirectly,
solicit, induce, or encourage (or attempt to do so) any of the Company’s employees or other service providers to leave their employment/engagement,
or hire or take away such employees or other service providers, either for myself or for any other person or entity. This restriction
includes all those who were employed by or performed services for the Company at any time during the one year period immediately before
the date my employment terminated.

 

    2

     

    

 

In addition, during my employment and for a period
of one year immediately following the termination of my employment with the Company for any reason, I will not, either directly or
indirectly: (a) interfere with the Company’s relationships with any of its customers, prospective customers, suppliers, contractors,
distribution partners, prospective distribution partners, resellers, or any third party regularly dealing with the Company; or (b) solicit,
call upon, divert or actively take away, or attempt to solicit, call upon, divert or take away, for purposes of conducting a business
substantially similar to or competitive with the Company’s business, any of the Company’s customers, prospective customers,
suppliers, contractors, distribution partners, prospective distribution partners, or other third party regularly dealing with the Company.
This restriction includes any customer to which the Company sold any product, or for which the Company performed any service at any time
during the one year period immediately before the date my employment terminated, except that the restriction pertaining to the Company’s
prospective customers only applies if I became familiar with the prospective customer through my employment.

 

4.             COVENANT
NOT TO COMPETE. To protect the Company’s Proprietary Information, I agree that during
my employment and for a period time equal to the duration of my employment with the Company plus six months, commencing immediately following
the termination of my employment with the Company for any reason, I will not compete with the Company in the Territory (defined below),
which for clarity means that I will not, either directly or indirectly, in the Territory (i) serve as a consultant, director, manager,
employee, officer, partner, or proprietor, for any Restricted Business (defined below); (ii) have any ownership interest in any Restricted
Business other than a passive ownership interest of two percent or less in an entity whose securities are publicly traded; or (iii) participate
in the organization, financing, operation, management or control of any Restricted Business. “Restricted Business”
means business in competition with the Company’s business as conducted by the Company at any time during the course of my employment
with the Company, together with any other business with which I am actively involved in assisting the Company with researching, developing
or marketing at the time of the termination of my employment. For clarity, the Company’s business as of the date I signed this Agreement
includes research and development of monoclonal antibodies directed to the inhibition of HER3 (human epidermal growth factor receptor
3). For further clarity, this covenant does not prohibit my employment with competitors of the Company, if the area in which I will be
employed/engaged is different from the area of my employment/engagement with the Company and will not require or inevitably lead to the
disclosure of the Company’s Proprietary Information. “Territory” means: (i) the entire world; (ii) North
America; (iii) the United States of America; (iv) each state in which the Company does business or did business at any time
within one year prior to the termination of my employment with the Company; (v) the States of New York, Massachusetts, Pennsylvania,
Connecticut, and New Jersey; (vi) the State of New York; and (vii) New York County. The foregoing Territory is reasonable and
reasonably necessary to protect the Proprietary Information. If, however, a court determines that the Territory described above in subparagraph
(i) is too restrictive, then the parties agree the Territory shall be reduced to the area specified in each of the following subsections
and in the following order until the court determines an acceptable geographic area: subparagraphs (ii), (iii), (iv), (v), (vi) or
(vii). If the court determines that all of the areas are too restrictive, then the parties agree that the court may reduce or limit the
area to enable the intent of this Section to be enforced in the largest acceptable area. Notwithstanding the foregoing, the obligations
under this Section 4 shall be of no further force and effect if the Company does not complete the “Milestone Closing”
contemplated by the Series A Preferred Stock Purchase Agreement entered into on or about the date of this Agreement.

 

    3

     

    

 

5.             REASONABLE.
The nature of the Company’s products and services are such that its natural market is worldwide. The restrictions in Sections 3
and 4 are reasonable and are reasonably necessary for the protection of Proprietary Information and provide a reasonable way of protecting
the Company’s business value which will be imparted to me. Through my employment I will receive adequate consideration for any loss
of opportunity associated with their provisions. The length of time, geographic area and any other restrictions contained in this Agreement
are reasonable to protect the legitimate interests of the Company and do not unfairly restrict or penalize me. However, if any restriction
set forth in Section 3 is found by a court to be unenforceable because it extends for too long a period of time or over too great
a range of activities or in too broad a geographic area, it shall extend only over the maximum period of time, range of activities or
geographic area as to which such court shall determine it to be enforceable. A breach of any provision(s) of this Agreement tolls
the running of the limitation period and the restriction period with respect to such provision(s) during the breach.

 

6.             NON-DISPARAGEMENT.
At all times during my employment and afterwards I will not, directly or indirectly, disparage the Company, its officers or directors,
its business, services, products or personnel. This provision is not intended to restrict communications or actions legally protected
by state or federal law, including the National Labor Relations Act.

 

7.             USE
OF LIKENESS. I will not, directly or indirectly, endorse, speak on behalf of, or allow my name
or likeness to be used to in any way promote any competitive business or competing product during my employment with the Company. During
my employment and after my employment with the Company ends, I consent to the Company’s use of my image, likeness, voice, and
other characteristics in connection with the Company’s operation of the Company’s business and its promotion and sale of its
products and services. I release the Company from any cause of action which I may have or may have arising out of the use, distribution,
adaptation, reproduction, broadcast, or exhibition of such characteristics.

 

8.             SOCIAL
MEDIA. The Company owns all Company-related digital and social media accounts (including all
passwords, data posts, digital works and goodwill therein) that I may create, manage, contribute to, or administer during my employment
with the Company and including all “followers,” connections, fans, subscribers, contacts and other relationships created under
such accounts. My use of such accounts will be in accordance with all Company policies in effect from time to time. At any time upon request
and immediately upon my termination of employment for any reason, I will surrender full control and access to such accounts to the
Company.

 

9.             LEGAL
AND EQUITABLE REMEDIES. Because my services are personal and unique and the Company may not have
an adequate remedy at law for a breach or threatened breach of this Agreement, the Company may, in addition to other remedies at law or
in equity which may be available, enforce this Agreement by injunction, specific performance or other equitable relief, all without bond.

 

    4

     

    

 

10.           EMPLOYMENT
AT-WILL AND OTHER MATTERS. My employment is at-will, meaning that I or the Company can end my
employment at any time for any reason. The Company may notify any employer I may have in the future of my rights and obligations under
this Agreement. At any time upon request and on termination of my employment, I will return all Company property to the Company immediately.
In addition, all Company property and property situated on the Company’s premises is subject to inspection by the Company at any
time and I understand that I have no expectation of privacy with regard to the same, including without limitation work areas, computer
and communications systems, email and internet records handheld devices or other property used to conduct the business of the Company.
Nothing in this Agreement is intended to limit my rights to discuss the terms, wages, and working conditions of employment, as protected
by applicable law.

 

11.           GENERAL
PROVISIONS. Delaware law governs this Agreement. I consent to the personal jurisdiction of and
venue in the state and federal courts located in Delaware. If any provision of this Agreement is found invalid or unenforceable, no other
provision is affected. This Agreement is binding on my heirs and all legal representatives. This Agreement benefits and may be enforced
by the Company and its agents, parents, subsidiaries, affiliates, successors and assigns. The provisions of this Agreement survive the
termination of my employment and the assignment of this Agreement by the Company to any assignee or successor. A waiver by the Company
of any breach is not a waiver of any prior or subsequent breach, and a waiver of any specific right shall not be construed as a waiver
of any other right. For purposes of this Agreement, the term “employee” shall be deemed to include “consultant,”
 “independent contractor” or “director,” and the term “employment,” or any variation thereof, shall
be deemed to include “engagement” or any variation thereof. My obligations under this Agreement shall apply to any time during
which I was previously employed, or am in the future employed, by the Company if no other agreement governs during such period. Any subsequent
change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement. This Agreement is effective
as of the first day of my employment with the Company. This Agreement is the final, complete and exclusive agreement between me and the
Company with respect to the subject matter hereof and supersedes all prior discussions or agreements, written or verbal, between us with
respect to the subject matter hereof. Amendments or waivers to this Agreement must be in writing and signed by the party to be charged
to be effective.

  

	I
    HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.	 	ACCEPTED
    AND AGREED TO:
	 	 	14NER
    ONCOLOGY, INC.
	 	 	 
	Dated:
	July 12, 2019
	 	 

 

	/s/ Shawn Leland 	 	By: 	/s/ Steve Elms

	Signature/Printed Name	 	 Signature/Printed Name

 

	[*****]	 	Title: 	CEO
	[*****]	 	 	 
	Address 	 	 	 

 

    5

     

    

 

******************************************************************************

“PRIOR INVENTIONS”

 

******************************************************************************

 

 

If you have Prior Inventions, please list them
in the space below. If no Prior Inventions are identified below, you are affirming that you have no Prior Inventions to identify. If you
need extra pages, please attach them and indicate below.

 

	Title	Date of Prior Invention	Brief Description

 

If a prior confidentiality agreement prevents
disclosure above, instead provide a cursory name for each prior invention, a listing of the party or parties to whom it belongs and description
of the relationship to that party.

 

	Invention	Parties	Relationship

 

 

******************************************************************************

 

    1

     

    

 

FIRST
AMENDMENT TO

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS FIRST AMENDMENT TO EXECUTIVE
EMPLOYMENT AGREEMENT (the “Amendment”) is entered into as of January 6, 2021 (the “Effective Date”)
by and between Elevation Oncology, Inc. (f/k/a 14ner Oncology, Inc., the “Company”) and Shawn Leland (the
 “Executive;” and, together with the Company, the “Parties”), who agree to be bound by all of the
terms and conditions hereof.

 

W I T N E S S E T H:

 

WHEREAS, the Executive and
the Company entered into a letter agreement on July 12, 2019 (the “Employment Agreement”), setting forth the terms
and conditions of Executive’s employment with the Company; and

 

WHEREAS, the Executive and
the Company desire to amend the Employment Agreement at this time as set forth in this Amendment.

 

NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Executive and the Company hereby amend the Employment
Agreement as follows, effective as of the date hereof:

 

1.            Section 2
of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

“2. Effective
as of November 13, 2020, your base salary will be at the rate of $35,416.66 per month (equivalent to an annualized base salary of
$425,000), subject to tax and other withholdings as required by law, and will be paid on the regularly scheduled payroll dates of the
Company. The Board may elect to increase your base salary periodically based on your performance and/or industry standards for similarly
situated executives.”

 

2.            Section 3
of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

“3. Effective
January 1, 2021, following the end of each fiscal year and subject to the approval of the Company’s Board (or a committee thereof),
you will be eligible for a retention and performance bonus, targeted at 50% of your annualized base salary as determined by the Board
(or a committee thereof) in good faith based on your individual performance and the Company’s performance during the applicable
fiscal year. If a bonus is awarded, unless otherwise specifically provided by the Board or committee administering such plan, it shall
be paid on or before January 31st of the year following the year in which such bonus was earned. You must be an active employee of
the Company on the date any bonus is distributed in order to be eligible for and to earn a bonus award, as it also serves as an incentive
to remain employed by the Company. The Board may elect to increase your retention and performance bonus target based on your performance
and/or industry standards for similarly situated executives.”

 

    1

     

    

 

3.            Section 9
of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

“9. Without
otherwise limiting the “at-will” nature of your employment, if your employment is terminated by the Company without Cause
or by you for Good Reason (each as defined below), and provided you execute and allow to become effective (within 60 days following the
termination or such shorter period (of not less than twenty-one (21) days) as may be directed by the Company) a severance and release
of claims agreement in a form prescribed by the Company (which will include, at a minimum, a release of all releasable claims and post-employment
confidentiality, non-disparagement, non-competition, non- solicitation and cooperation obligations) (the “Release Agreement”),
the Company will pay you as severance pay an aggregate amount equivalent to twelve (12) months of your then current base salary, less
all applicable taxes and withholdings, which severance pay will be paid ratably in accordance with the Company’s regular payroll
practices beginning in the Company’s first regular payroll cycle after the Release Agreement becomes effective; provided, however,
that if the 60th day referenced above occurs in the calendar year following the date of your termination, then the severance pay shall
begin no earlier than January 1 of such subsequent calendar year. During the twelve (12) month severance period, the Company will
bear the cost of health insurance for you and your immediate family on substantially the terms applicable prior to the termination of
your employment.”

 

4.            This
Amendment is hereby incorporated into and forms a part of the Employment Agreement.

 

5.            Except
as expressly modified herein, all terms, covenants and conditions of the Employment Agreement will remain in full force and effect. The
Parties do expressly ratify and confirm the terms of the Employment Agreement as amended herein.

 

6.            This
Amendment shall be binding upon the Parties hereto and upon their respective heirs, legal representatives, successors and permitted assigns
and shall be governed by and construed in accordance with the laws of the State of Delaware.

 

7.            This
Amendment may be executed by one or more of the Parties in any number of separate counterparts, each of which shall be deemed an original
and all of which, taken together, shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart signature
to this Amendment by electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

 

[The remainder of this page is intentionally
left blank.]

 

    2

     

    

 

IN WITNESS WHEREOF, the Parties
have executed this First Amendment to Executive Employment Agreement as of the day and year first above written.

 

	 	COMPANY:
	 	 
	 	ELEVATION ONCOLOGY, INC.

	 	By:	/s/ Steven Elms

 

	 	Name: Steven Elms
	 	Title: Chairman
	 	 
	 	EXECUTIVE:

 

	 	/s/ Shawn M. Leland
	 	Shawn Leland

 

    1

     

    

 

FIRST
AMENDMENT TO

PROPRIETARY INFORMATION, INVENTIONS,

NON-COMPETITION AND NON-SOLICITATION AGREEMENT

 

THIS FIRST AMENDMENT TO PROPRIETARY
INFORMATION, INVENTIONS, NON-COMPETITION AND NON-SOLICITATION AGREEMENT (the “Amendment”) is entered into as of
January 6, 2021, by and between Elevation Oncology, Inc. (f/k/a 14ner Oncology, Inc., the “Company”)
and Shawn Leland (the “Executive;” and, together with the Company, the “Parties”), who agree to
be bound by all of the terms and conditions hereof.

 

W I T N E S S E T H

 

WHEREAS, the Company and Employee
are parties to that certain Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement dated July 12,
2019 (the “Proprietary Information Agreement”);

 

WHEREAS, the Company and Executive
desire to amend the Proprietary Information Agreement at this time as set forth in this Amendment; and

 

WHEREAS, this Amendment is
made in connection with and in consideration for (i) the amendment of a letter agreement, dated July 12, 2019, between the Parties
to increase the Executive’s compensation and extend his severance period from six months to twelve months, and (ii) the issuance
to the Executive of an incentive stock option to purchase up to 2,276,050 shares of the common stock of the Company.

 

NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Executive and the Company hereby amend the Proprietary
Information Agreement as follows, effective as of the date hereof:

 

1.             The
first sentence of Section 4 of the Proprietary Information Agreement is hereby amended and restated as follows:

 

“To protect the Company’s
Proprietary Information, I agree that during my employment and for a period time equal to the duration of my employment with the
Company plus twelve months, commencing immediately following the termination of my employment with the Company for any reason, I
will not compete with the Company in the Territory (defined below), which for clarity means that I will not, either directly or indirectly,
in the Territory (i) serve as a consultant, director, manager, employee, officer, partner, or proprietor, for any Restricted Business
(defined below); (ii) have any ownership interest in any Restricted Business other than a passive ownership interest of two percent
or less in an entity whose securities are publicly traded; or (iii) participate in the organization, financing, operation, management
or control of any Restricted Business.”

 

2.             Except
as expressly modified herein, all terms, covenants and conditions of the Proprietary Information Agreement will remain in full force and
effect. The Parties do expressly ratify and confirm the terms of the Proprietary Information Agreement as amended herein.

 

    1

     

    

 

3.             This
Amendment shall be binding upon the Parties hereto and upon their respective heirs, legal representatives, successors and permitted assigns
and shall be governed by and construed in accordance with the laws of the State of Delaware.

 

4.             This
Amendment may be executed by one or more of the Parties in any number of separate counterparts, each of which shall be deemed an original
and all of which, taken together, shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart signature
to this Amendment by electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

 

[The remainder of this page is intentionally
left blank.]

 

    2

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this First Amendment to Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement
as of the day and year first above written.

 

	 	COMPANY:
	 	 
	 	ELEVATION ONCOLOGY, INC.

 

	 	By:	/s/ Steven Elms

	 	Name: Steven Elms
	 	Title: Chairman

 

	 	EXECUTIVE:
	 	 
	 	/s/ Shawn M. Leland
	 	Shawn Leland

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]